Clinical Trial Update: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of KA2237, a PI3K p110β/δ inhibitor, in B-cell lymphoma reports on safety, pharmacokinetics and pharmacodynamics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• KA2237

Snippet

Sponsor: Karus Therapeutics Limited | Conditions: Lymphoma, B Cell | Phase 1 | Status: COMPLETED